Answers are grounded in this paper and cite their sources.
Dipeptidyl peptidase-4 (DPP-4) inhibitors represent a new class of oral antihyperglycemic agents to treat patients with type 2 diabetes.1 DPP-4 inhibitors improve fasting and postprandial glycemic control without hypoglycemia or weight gain.1 This article focuses on the physiology, clinical pharmacology, tolerability, and clinical utility of the DPP-4 inhibitor sitagliptin in the management of type 2 diabetes. Clinical Pharmacology & Therapeutics (2007) 81, 761–767. doi:10.1038/sj.clpt.6100167; published online 28 March 2007
No takes yet. Share an insight, caveat, or question.
Herman et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: